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Background: Hyperglycemia exacerbates brain damage caused by cerebral ischemia. Neuroinflammation may play
a role in mediating such enhanced damage. The objectives of this study were to examine the mRNA and protein
levels and cell type distribution of ICAM-1 after cerebral ischemia in normo-and diabetic hyperglycemic rats.
Results: Compared to normoglycemic ischemia animals, diabetes aggravated neuronal death, decreased Nissl body
staining, and increased ICAM-1 mRNA and protein levels in the frontal cortex. The increased ICAM-1 was located
not only in vascular endothelial cells but also in cortical neurons.
Conclusions: Our results suggest that exacerbated neuro-inflammation in the brain may mediate the detrimental
effects of diabetes on the ischemic brain.
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StrokeBackground
It has been well established that preischemic hypergly-
cemia exacerbates ischemia induced neuronal damage
and augments the infarct size [1,2]. The exact mechanisms
of diabetic hyperglycemia exacerbating ischemia are not
fully understood. However, studies have shown that hyper-
glycemia produces lactic acid, increases free radical for-
mation, activates the intrinsic cell death pathway, disrupts
the blood– brain barrier (BBB), and induces local inflam-
mation [3].
Recent studies suggest that inflammation plays an
important role in the occurrence and development of
ischemic brain damage [2]. The infiltration of polymor-
phonuclear leukocyte (PMN) into ischemic brain tissue
has been demonstrated in several animal models of stroke
[4]. Cerebral ischemia results in vascular endothelial cell* Correspondence: zhangjz@nxmu.edu.cn; pli@nccu.edu
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unless otherwise stated.injury, leading to the expression of cell adhesion mole-
cules and attracting PMN to attach to endothelial cells,
which then migrate to ischemic tissue where they: release
pro-inflammatory cytokines, produce free radicals and ac-
tivate microglia [5]. The recruitment of circulating PMNs
into ischemic tissue initially requires the interaction of
microvascular endothelial cells with these inflammatory
cells via specific adhesion molecules [6]. The expression of
cell adhesion molecules and release of inflammatory cy-
tokines are early events after ischemia and reperfusion.
Several cell adhesion molecules are known to play critical
roles in the cell surface interactions between endothelial
cells and PMNs. One of the best-known adhesion mole-
cules found on the endothelial cell surface is intercellular
cell adhesion molecule 1 (ICAM-1) [6]. ICAM-1 is a gly-
coprotein that is expressed on the membrane of the vas-
cular endothelium and other cells. It is upregulated by
endotoxin and several cytokines including TNF-α, IL-1
and IFN-γ both in vitro and in vivo [7-9]. In addition
to the activation of endothelial cells and trans-endothelial
migration of PMN, the expression of ICAM-1 plays
an important role in inducing neuro-inflammation and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stroke [2]. Prevention of ICAM-1 expression by antisense
infusion significantly decreases infarct size and the neuro-
logical deficits caused by transient focal ischemia [10,11].
Diabetic patients have an increased risk of developing
cardiovascular disease and inflammatory microvascular
complications in organs such as blood vessels, brain,
heart, kidneys and retina. Hyperglycemia, the hallmark
of diabetes, initiates macro- and microvascular complica-
tions in part by inducing an endothelial inflammatory
phenotype [12]. Hyperglycemia upregulates cell adhesion
molecules expressed on the vascular endothelium, a process
known to induce pathological leukocyte-endothelium in-
teractions. Recent evidence suggests that ICAM-1 not
only promotes atherogenesis [13] but also exacerbates
organ damage [12,14]. Although we and others have previ-
ously observed that ICAM and other pro-inflammatory
cytokines are increased in diabetic animals after cerebral
ischemia and reperfusion [15,16], these finding were con-
fined to blood vessels and short period of reperfusion
phases. The objective of this study was to characterize the
ICAM expression pattern and its cellular localization after




Male Sprague-Dewley rats with body weights of 240-350 g
were provided by the Medical Experiment Animal Center
of Ningxia Medical University. All animal usage and
procedures were in strict accordance with the Chinese
Laboratory Animal Use Regulations. Efforts were made to
minimize animal stress and to reduce the number of rats
used for this study.
Polyclonal anti-GFAP antibody (Santa Cruz), monoclonal
anti-NeuN antibody (Sigma), polyclonal anti-ICAM-1 anti-
body (Protect), polyclonal anti-β-actin antibody (Sigma),
horseradish peroxidase-conjugated anti-mouse secondary
antibody (Sigma), and streptozotocin (STZ, Calbiochem,
Germany) and the ICAM-1 In Situ Hybridization Detec-
tion kit were purchased from Boster Biotechnology Co
(Wuhan, China).
STZ-induced diabetic hyperglycemia
The rats were injected intraperitoneally with streptozoto-
cin (STZ, 55 mg/kg, in 0.1 mol/l citrate buffered saline,
pH 4.5). Age-matched rats receiving the same volume of
citrate-buffered saline served as normoglycemic controls.
Blood glucose levels were measured 2–3 days after STZ
injection to verify the success of diabetes induction. Those
with glucose > 16 mmol/L were included in diabetic group.
Cerebral ischemia was induced 7 days later in the STZ-
induced diabetic and citrate buffer-injected non-diabetic
animals.Experimental groups
Rats were randomly divided into three groups: (1) a sham-
operated control group consisting of a normoglycemic
and a hyperglycemic subgroup (n = 10); (2) a normogly-
cemic ischemic group (n = 20); and (3) a diabetic ischemic
group (n = 20). The animals in the two ischemic groups
(groups 2 and 3) were further divided into 4 sub-groups,
namely 8 minutes of ischemia with 1-, 3-, and 6-days of
reperfusion (n = 5 in each subgroup).
Ischemic model
Both diabetic hyperglycemic and non-diabetic normogly-
cemic animals were subjected to an 8-min duration of
forebrain ischemia induced by bilateral clamping of the
common carotid arteries after exsanguinations from a fem-
oral artery, maintaining blood pressure at 40–50 mmHg
[17]. Brain ischemia was confirmed by an isoelectric EEG.
The rats were revived after re-infusing the shed blood and
releasing the ligatures placed around the carotid arteries.
At the pre-determined time points, animals were eutha-
nized, and their brains were removed. The brains were
divided into left and right hemispheres. One half of the
hemisphere was fixed in 4% paraformaldehyde buffer, proc-
essed and embedded in paraffin, and then sectioned at
5 μm intervals for histology and immunohistochemistry
studies. The second half of the hemisphere was used for
extraction of RNA and protein.
Pischingert staining
After 10 minutes of incubation at room temperature in
methylene blue solution, the sections were washed in
PBS (pH 4.6) until the Nissl bodies were clearly visualized.
The sections were then incubated with 4% ammonium
molybdate buffer for 5 minutes. Neurons with Nissl body
staining intensity decreased to less than 50% of the inten-
sity of the control animals were defined as degenerative
neurons.
Real-time quantitative PCR
Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, California, USA,) according to the manufacturer’s
protocol. The total RNA concentration was assessed by
measuring the absorbance at 260 nm using a Nano Drop
Spectrophotometer (ND-1000, Thermo Scientific, USA).
Reverse transcription (RT) for synthesizing the first-strand
of the cDNA was performed with 2 μg of total RNA
treated with M-MLV reverse transcriptase according to
the manufacturer’s recommendations (Promega, USA).
The resulting cDNA was then subjected to real-time
quantitative PCR for evaluation of the relative mRNA
levels of ICAM-1 and β-actin (as an internal control).
Gene-specific amplification was performed using an
ABI 7900HT real-time PCR system (Life Technologies,
Carlsbad, California, USA) with a 15-μl PCR mix containing
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(Invitrogen, Carlsbad, California, USA), and 200 nM of
the appropriate oligonucleotide primers. The mix was
preheated at 95°C (10 min) and then amplified at 95°C
(30 sec) and 60°C (1 min) for 40 cycles. The Ct (threshold
cycle) value of each sample was calculated from the
threshold cycles using the instrument’s software (SDS 2.3),
and the relative expression of the ICAM-1 mRNA was
normalized to the β-actin value. The Ct values (num-
ber of the threshold cycle) of each sample were recor-
ded. The difference in ICAM–1 gene expression was
compared by varying the rate. The rate = 2-ΔCt was varied,
where ΔCt = (the Ct values of ICAM-1 in experimental
group - the Ct values of β-actin in experimental group) -
(the Ct values of ICAM-1 in sham control group-the Ct
values of β-actin in sham control group). A relative ex-
pression change of more than 40% was considered signifi-
cantly different. Beta-actin mRNA was used as a control
for ICAM-1 mRNA, and normal rats were used as nega-
tive controls.Western blot analysis
Western blotting was employed to test whether upregu-
lation of ICAM-1 mRNA led to an increase in ICAM-1
protein translation in the hyperglycemic animals. Western
blotting was performed as previously described [18]. Brain
tissues were homogenized using lysis buffer, and protein
concentrations were measured using the Microplate BCA
Protein Assay kit (Thermo Scientific). Equal amounts of
protein (5 μg) were loaded on a 10% SDS-polyacrylamide
gel and transferred to nitrocellulose membrane for 1 hour
at 100 Volt. After being blocked with 5% non-fat milk, the
membranes were incubated for 24 hours (4°C) using an
anti-ICAM-1antibody (1:1000 dilution). Immunoreactivity
was visualized using a Western blotting detection kit. Pro-
tein bands were scanned, and the optical density (OD)
was measured using a computer imaging analysis system
(Bio-Rad Co.).In Situ hybridization
Digoxigenin-labeled riboprobes, synthesized by Wuhan
Boster Biological Engineering Limited (Wuhan China),
were used for the detection of rat ICAM-1 and β-actin








The probe specificity was confirmed by BLAST soft-
ware testing.In situ hybridization was performed as previously
reported [19]. Briefly, after regular sequence treatment,
the sections were incubated with 20 μl of pre-hybridi-
zation solution for 3 hours (38-42°C). The sections were
incubated with sense or anti-sense (control) riboprobe
hybridization solution overnight (38-42°C). The reaction
was stopped by applying blocking solution on the sec-
tions. Biotinylated mouse anti-digoxigenin was applied
on the sections for 60 min (37°C), and followed by
reaction with SABC. Biotin-peroxidase complex was
applied, and diaminobezidine (DAB) was used as a sub-
strate. The sections were counterstained with hematoxylin
and mounted. The images were analyzed under a light
microscope and are presented as a ratio of positively
stained cells to total cells for an area of 50 mm2. Brown
particles in the cytoplasm were considered a positive
signal.Immunohistochemistry
Sections were treated with 3% H2O2 for 10 min at room
temperature to quench endogenous peroxidase activity.
Antigen retrival was achieved by heating sections im-
mersed in sodium citrate buffer (pH 6.0) for 10 min
using a microwave oven. The sections were incubated
overnight (4°C) with primary antibodies against GFAP at
1:800 and ICAM-1 at 1:100. The sections were washed
and then incubated with a horseradish peroxidase (HRP)
conjugated secondary antibody (1:300, Santa Cruz). Color
reaction was achieved by DAB incubation for 3 min at
room temperature. The sections were then rinsed in dis-
tilled water and counterstained with hematoxylin. The
sections were cover-slipped and analyzed using a com-
puter image analysis system (Zeiss LSM5 Image Examiner
software).
The immunofluorescent double labeling of ICAM-1
with the astrocyte marker GFAP or with the neuronal
marker NeuN was also performed using the afore-
mentioned antibodies. The double labeling of ICAM-1
and GFAP or ICAM-1 and NeuN was achieved by incu-
bating with the two primary antibodies separately and
then with a mixture of the two fluorescence-conjugated
secondary antibodies. The specimens were mounted with
Vectashield Hardset Mounting Media (H-1200, Vector)
containing 4′, 6-diamidino-2-phenylindole (DAPI) and
examined using a fluorescence confocal-scanning mi-
croscope (Nikon Eclipse C1).Statistical analysis
The values are expressed as the mean ± SEM. ANOVA
followed by Tukey’s test was employed for statistical
analysis among the three groups, and Student’s t-test
was used to analyze data between two groups. P < 0.05
was considered to be statistically significant.
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Blood glucose alterations in rats
Diabetes was induced in the animals through streptozo-
tocin injection (STZ, 55 mg/kg). The diabetic condition
was confirmed in the rats through measurements of
blood glucose levels 2 days after the STZ injection. Fast-
ing blood glucose levels were measured again 10 min
before the induction of cerebral ischemia. The mean blood
glucose values were 5.72 ± 0.71 mmol/L for the normogly-
cemic animals and 19.98 ± 2.32 mmol/L for the diabetic
animals (P < 0.01).
Histological changes
In this study, morphologic changes of the cerebral
frontal cortex were detected using hematoxylin and eosin
(H&E). As expected, there were no obvious cerebral struc-
tural abnormalities observed in the sham-operated nor-
moglycemic and diabetic animals (Figure 1A and D). In
the normoglycemic animals, transient forebrain ischemia
for 8 min induced a mild brain edema at 1-day of reperfu-
sion, which was identified by the increased swelling of the
neuronal cell bodies and nucleus, and the widened inter-
cellular space of the neurons, astrocytes and endothelial
cells. At 3-day reperfusion, the brain edema was further in-
creased. In addition, cellular swelling and the disappear-
ance of the nucleolus were observed in a few neurons
in the bilateral cerebral frontal cortex (Figure 1B). At
this time point (3 days), a reduced number of neurons
was observed. Some neurons showed abnormal cyto-
plasmic changes with pale staining, vacuolar degener-
ation, or dissolved nuclei. Although the brain edema
was extenuated by 6 days of reperfusion, the neuronalFigure 1 Brain morphological changes in the frontal cortex after 8 min
and hyperglycemic animals. (A,D) Typical appearance of brain tissues in no
neuronal swelling in normoglycemic ischemic animals after 3 and 6 days of re
hyperglycemic animals after 3 and 6 days of reperfusion. Arrows indicate tissu
400X, bar = 20 μm.damage had progressed significantly (Figure 1E). In the dia-
betic ischemic animals, the brain edema was clearly aggra-
vated, and a more extensive loss of neurons and glial cells
was observed compared to the normoglycemic ischemic
group (Figure 1C). At 6 days of reperfusion, a large number
of neural cells exhibited a shrunken triangular pyramidal
cell body and pyknosis with deep staining (Figure 1F), sug-
gesting these cells were undergoing degeneration or death.
Neuro-degeneration detected by Pischingert staining
The Nissl bodies of neurons were stained by Pischingert
and appeared as deep blue particles. The reduction or
absence of Nissl bodies suggests the hydropic degener-
ation of neurons. The granular blue staining of the Nissl
substance was uniformly detected in the cytoplasm of
the frontal cortex of the sham-operated normoglycemic
and diabetic hyperglycemic animals (Figure 2A and D). In
the normoglycemic ischemic rats, the mean optical density
[integral optical density (IOD)/Sum area] of the Pischingert
staining was significantly decreased in the frontal cortex
after 1, 3 and 6 days of reperfusion (Figure 2B, E and G). In
comparison, diabetic forebrain ischemia induced a further
decreased or even dissolved staining of the Nissl bodies
(Figure 2C and F). As a result, the mean optical density of
the Pischingert staining was significantly lower compared
to the normoglycemic ischemic animals, especially at 1
and 3 days of reperfusion (Figure 2G). The numbers of
degenerative neurons, as defined by a greater than 50%
reduction of Nissl body staining, were counted in all three
groups at 1, 3 and 6 days of reperfusion. Eight minutes of
forebrain ischemia resulted in neurodegeneration in the
frontal cortex from 1–6 days of reperfusion. Preischemicof cerebral forebrain ischemia and reperfusion in normoglycemic
rmo- and hyperglycemic sham control animals. (B,E) Brain edema and
perfusion. (C,F) Enhanced brain edema and neuronal death in
e or neuronal swelling; arrowheads denote neuronal death. Magnification
Figure 2 Pischingert staining of the Nissl bodies in neurons of the frontal cortex after ischemia and reperfusion in normo- and
hyperglycemic ischemic rats. (A,D) Normal Nissl substances were stained in the cytoplasm of sham control animals. (B,E) Decreased staining
intensity observed in normoglycemic ischemia rats. (C,F) Significantly weaker staining of Nissl substances in hyperglycemic ischemic rats. (G) Bar
graph indicating the mean optical density (OD) of the Nissl bodies in the three groups at different reperfusion times. (H) The number of degenerative
neurons in the cerebral frontal cortex. Arrows indicate positive Pischingert staining of the Nissl bodies. *P < 0.05 vs. sham group, #P < 0.05 vs.
normoglycemic group at an identical reperfusion stage. Magnification, 400X, bar = 20 μm.
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tive neurons compared to the normoglycemic ischemic
animals at an identical reperfusion stage (Figure 2H).
ICAM-1 mRNA level
ICAM-1 mRNA levels were detected by reverse transcrip-
tion-polymerase chain reaction (RT-PCR). The Ct values
(number of threshold cycle) of each foramen were recorded
and compared. The results showed that the ICAM-1
mRNA levels were up-regulated after 1, 3, and 6 days of
reperfusion in the normoglycemic rats and that diabetes
further up-regulated the expression of the post-ischemic
ICAM levels. The original RT-PCR recordings are presen-
ted in Figure 3A, and the summarized data are presented in
Figure 3B.
ICAM-1 protein level
The changes in the ICAM-1 protein levels in the frontal
cortex after 8 min of cerebral ischemia in both the
normoglycemic and diabetic hyperglycemic groups were
analyzed by Western blotting. Band intensities were
measured using the Bio-Rad gel-imaging system. As
shown in Figure 4, compared to the normoglycemic ani-
mals, hyperglycemia significantly increased the ICAM-1
protein levels at 3 and 6 days of reperfusion in the
frontal cortex.ICAM-1 mRNA in situ hybridization
Almost no ICAM-1 positive cells were detected in the
frontal cortex of the sham control animals, and only the
occasional few scattered positively stained neurons were
detected. In contrast, the number of ICAM-1 mRNA
positive cells was increased after 1 day and further in-
creased after 3 days of reperfusion in normoglycemic rats
subjected to 8 min of forebrain ischemia. Compared to the
normoglycemic ischemic group, hyperglycemia increased
the expression of ICAM-1 mRNA at 3 and 6 days of
reperfusion. Examples of ICAM-1 in situ hybridization are
shown in Figure 5A-F, and the summarized ICAM-1 mean
optical density data [=integral optical density (IOD)/Sum
area] are provided in Figure 5G.
ICAM-1 cellular localization
ICAM-1 localization was detected using immunofluo-
rescent staining in brain sections obtained from sham,
normoglycemic ischemic and hyperglycemic ischemic ani-
mals. Weak ICAM-1 immunostaining was observed in the
small blood vessels of the sham operated animal brain sec-
tions (Figure 6A and D). Eight minutes of cerebral ische-
mia induced the increased immunoreactivity of ICAM-1 in
the small blood vessels of the normoglycemic animals at 3
and 6 days of reperfusion (Figure 6B and E). Diabetic ische-
mia further enhanced the ICAM-1 immunoreactivity in
Figure 3 ICAM-1 mRNA levels detected by RT-PCR. (A) Examples of original RT-PCR recordings. (B) Bar graph summarizing ICAM-1 mRNA
expression levels in the three groups. *P < 0.05 vs. sham group, #P < 0.05 vs. normoglycemic group at an identical reperfusion stage. I/R, ischemia
and reperfusion.
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(Figure 6C and F).
To examine whether ICAM-1 localized in other types
of brain cells in addition to vascular endothelial cells, we
performed double immune labeling of f ICAM-1 with
the astrocyte marker GFAP, or the neuronal marker
NeuN. The results showed that there was no colocaliza-
tion of ICAM-1 with GFAP among the sham control,
normoglycemic ischemic or hyperglycemic ischemic brain
sections with up to 6 days of reperfusion (Figure 7A-C);
however, both the numbers of GFAP-positive astrocytes
and ICAM-1 positive cells increased independently after
ischemia and reperfusion in both the normo- and hyper-
glycemic animals. In contrast, ICAM-1 colocalized with
NeuN-positive neurons in the frontal cortex (Figure 7D-F).
ICAM-1 neuronal immunoreactivity was occasionally ob-
served in the sham-operated animals, increased in number
and fluorescent intensity after 3 days of reperfusion follow-
ing 8 min of ischemia, and were further aggravated by
hyperglycemic ischemia and reperfusion.Discussion
It has been well established that diabetes/hyperglycemia
exacerbates ischemic cerebral injury. Animal studies have
confirmed that hyperglycemia enhances ischemia-induced
brain edema, neuronal degeneration and mortality com-
pared with normoglycemic animals [18]. In this study, we
observed morphologic changes in the frontal cortex at 1, 3
and 6 days of reperfusion after 8 min of cerebral forebrain
ischemia with or without diabetic hyperglycemia. Histo-
logical studies using H&E staining and Pischingert stain-
ing confirmed the exacerbation effects of hyperglycemia
on neuronal death after ischemia, as reflected by the void
spaces around neurons or vessels and the decreases in the
Nissl bodies. Ideally, neurodegeneration should also be
detected using FluoroJade staining and TUNEL staining,
which is in addition to Pischingert staining. However,
because neuronal damage in the hyperglycemic ischemic
brain has been extensively studied and the main focus of
the current study is ICAM, we believe a combination of
Pischingert and H&E staining has satisfactorily revealed
Figure 5 ICAM-1 mRNA in situ hybridization. Images were taken of the frontal cortex. (A,D) Negatively stained brain sections from sham
controls. (B,E) ICAM-1 mRNA positive stained cells detected at 3 and 6 days of reperfusion in normoglycemic animals. (C,F) ICAM-1 mRNA positive
stained cells in diabetic animals. (G) Bar graph summarizes the mean optical density of ICAM-1 mRNA in samples collected from the frontal cortex.
Arrows indicate ICAM-1 positive neurons and arrow heads indicate ICAM-1 negative neurons. *P <0.05 vs. sham group; #P < 0.05 vs. normoglycemic
group at an identical reperfusion stage. I/R, ischemia and reperfusion. DAB visualization, weak haematoxylin counterstaining. Magnification, 400X,
bar = 20 μm.
Figure 4 ICAM-1 Western blotting. (A) Western blot for ICAM-1. (B) Summarized bar graph indicating semi-quantitative levels of ICAM-1 protein
in the normo- and hyperglycemic ischemic animals. N, normoglycemia; D, diabetes; and d, day. #P < 0.05 vs. normoglycemic group at an identical
reperfusion stage.
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Figure 7 Triple labeling of ICAM-1, GFAP and DAPI and double labeling of ICAM-1 and NeuN in the frontal cortex after 6 days of
reperfusion in normo- and hyperglycemic animals. (A-C) No colocalization of ICAM-1 with astrocytes; however, ischemia led to an increased
number of GFAP positive astrocytes. (D) Occasional ICAM-1 positively stained neurons were detected in the sham control animals. (E) Ischemia
increased the number of ICAM-1 positively stained neurons. (F) Diabetic hyperglycemia further increased the number of ICAM-1 positive neurons
in the frontal cortex. (G) Bar graph summarizes the average number of neurons positively labeled by anti-ICAM1 antibody. *P <0.05 vs. sham
group; #P < 0.05 vs. normoglycemic group at an identical reperfusion stage. Green color, ICAM-1; blue color, DAPI; red color, GFAP in A-C and
NeuN in D-F. Magnification, 400X.
Figure 6 ICAM-1 immunofluorescent staining (red color) in blood vessels of the frontal cortex. (A,D) Sham group. (B,E) Normoglycemic
ischemia after 3 and 6 days of reperfusion. (C,F) Hyperglycemic ischemia after 3 and 6 days of reperfusion. Red color, ICAM-1 staining, blue color,
DAPI. Magnification, 400X.
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mals. The factors that contribute to the adverse effects of
hyperglycemia on the ischemic brain are not fully
understood but may include tissue acidosis, the increased
production of oxygen and nitrogen free radicals, dam-
age to the mitochondria and the activation of neuro-
inflammation.
ICAM-1 plays an important role in initiating neuro-
inflammation after cerebral ischemia. ICAM-1, also
known as CD54 (Cluster of Differentiation 54), is a pro-
tein that is encoded by the ICAM-1 gene in humans
[20,21]. The ICAM-1 protein is continuously present in
low concentrations in the membranes of leukocytes and
endothelial cells. Upon cytokine stimulation, such as
interleukin-1 (IL-1) and tumor necrosis factor (TNF)
[22], the ICAM-1 concentration significantly increases,
and it is expressed in the vascular endothelium, macro-
phages, and lymphocytes. Once activated, leukocytes
bind to endothelial cells via ICAM-1/LFA-1 and then
transmigrate into tissues [23], where it induces free
radical production and the inflammatory cascade. In-
creased ICAM-1 further induces adhesion between vascu-
lar endothelial cells and leukocytes, impairs vascular
endothelial cells and increases the permeability of capillar-
ies, and eventually leads to brain damage [24,25]. It has
been reported that the expression of ICAM-1 and the in-
filtration of neutrophils into ischemic tissue are closely
correlated with the severity of ischemic brain damage [26].
The over-expression of ICAM-1 mRNA has been detected
at 3 hours, peaks at 6 hours and persists to 5 days of
reperfusion after middle cerebral artery occlusion [4], as
well as after intracerebral hemorrhage. In the present
study, we observed that ICAM-1 mRNA and protein
levels dramatically increased in brain cortical tissues after
1, 3 and 6 days of recovery following 8 min of forebrain
cerebral ischemia, suggesting ischemia induces inflam-
matory responses in the brain. We would like to note that
the rat brain was not perfused with PBS because we
wanted to extract brain tissue within 1 min of sacrifice to
minimize the potential chemical changes induced by artifi-
cial post-complete ischemia due to extended intervals be-
tween decapitation and tissue harvest. This protocol
might lead to an overestimation of ICAM-1 mRNA and
protein levels due to residual neutrophils in the cerebral
vessels. However, because the immunohistochemistry in-
dicated a clear neuronal localization of ICAM-1, we pre-
dict the observed increases in ICAM-1 are largely due to
an enhanced neuronal inflammatory response.
Diabetic hyperglycemia further enhanced the up-
regulation of ICAM-1 induced by ischemia. It is known
that hyperglycemia upregulates ICAM-1 in vascular
endothelial cells [27-29]. Such an activation leads to
inflammatory responses and to diabetic angiopathy and
retinopathy. Acute hyperglycemia, induced by glucoseinfusion for 10 min prior to the induction of 10 min of
forebrain ischemia, significantly increased the ICAM-1
protein levels in the brain homogenate and plasma
together with elevations in superoxide radicals, malon-
dialdehyde, high-mobility group box 1, and key markers
of lipid peroxidation [30]. However, the sample collec-
tion time was only limited to up to 120 min following
reperfusion. We have previously observed elevations of
ICAM-1 and IL-1β after a very brief period of forebrain
ischemia (5 min) in diabetic animals after 3 days of reperfu-
sion [15]. In the present study, we examined the ICAM-1
transcription and translation levels, as well as ICAM-1
localization up to 6 days of reperfusion following a moder-
ate period (8 min) of forebrain ischemia in normal and
diabetic rats. The results revealed that diabetic hypergly-
cemia further increased the mRNA and protein levels of
ICAM-1 in the frontal cortex after 1–6 days compared
with the normoglycemic ischemic animals, suggesting that
hyperglycemia aggravates ischemia-induced inflammation.
The molecular mechanism by which hyperglycemia fur-
ther enhances the expression of ICAM-1 is not fully
understood. Previous studies have suggested that hyper-
glycemia may cause ICAM-1 increases through the activa-
tion of IL-1β and the p38 MAPK pathway [15,29].
To further explore whether ICAM-1 is expressed in
cell types other than vascular endothelia, multiple im-
munolabelings of ICAM-1 with GFAP and NeuN were
performed. The results revealed that ICAM-1 co-localized
with cells other than astrocytes. The neuronal localization
of ICAM-1 has been previously observed in healthy and
inflamed choroid plexus [31] and dorsal root ganglia
neurons after sciatic nerve injury [32]. In the same study,
ICAM-1 immunoreactivity was also detected in Schwann
and satellite cells. Our results demonstrate that ICAM-1
is localized not only in cerebrovascular endothelial cells
but also in cortical neurons, implying diabetes leads to en-
hanced neuro-inflammation in post-ischemic brain tissues.
The mechanisms through which hyperglycemia activates
inflammatory responses are not fully understood. High
glucose levels increase ROS accumulation due to the en-
hancement of ROS production and depletion of glutathi-
one; the activation of the polyol, protein kinase C, MAPK
pathways; and the enhanced production of advance glyca-
tion end-products (AGE). These events lead to the acti-
vation of NF-кB and activator protein 1 (AP-1) and the
inhibition of nuclear factor (erythroid-derived 2)-like 2
(Nrf2). NF-кB is a potent inducer of inflammatory pro-
cesses through its upregulation of the gene expression of
proinflammatory cytokines and chemokines such as IL-1β,
IL-6, IL-17, TNF-α, c-reactive proteins, chemo attractant
protein 1, CCL-2 and CXC [33]. Nrf2 is a transcription
factor that upregulates several antioxidant enzymes. In a
recent study, Meng and colleagues demonstrated that dia-
betic hyperglycemia elicits neuro-inflammatory reactions
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zation domain (Nod) and Leucine-rich repeat containing
protein 1 (NLRP1) [34].
Conclusion
Diabetes mellitus leads to enhanced brain damage after
cerebral ischemia. Diabetes further increases ischemia-
induced ICAM-1 expression at the transcriptional and
translational levels. Furthermore, ICAM-1 immunoreac-
tivity was not only observed in vascular endothelial cells
but also in neurons. The results suggest that increased
neuro-inflammation may participate in mediating the
diabetes-augmented brain damage caused by transient
cerebral ischemia.
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